Abstract 60P
Background
The PI3K/AKT/mTOR pathway plays a major role in melanoma pathogenesis and is also involved in resistance to targeted therapies (TT). The mTORC2 complex plays an important role in this pathway allowing activation of AKT and contributes to the development of BRAF-mutated (BRAFm) melanomas and their resistance to treatments. Once activated, AKT phosphorylates several effector proteins, thus regulating multiple key cellular processes, including proliferation, survival, motility, metabolism and angiogenesis.The goal of our project is to study this complex in melanoma in order to target it specifically. For this purpose, we are focusing more particularly on one principal protein of this complex: SIN1 (also called MAPKAP1) involved in the stabilizing of mTORC2 complex, in its substrate’s specificity, and a major player in the total activation of AKT.
Methods
We are analysing SIN1 expression, by quantitative RT-PCR and IHC and its interaction with other proteins, by Proximity Ligation Assay (PLA), in situ in melanoma biopsies of the French national MELBASE cohort. We will correlate these results with clinico-biological data from MELBASE to determine if there is a diagnostic or prognostic value of these analyses. In a second step, we are mapping the minimal domain of SIN1/NRAS interaction by Peptide Array to develop cell-permeable peptides to inhibit NRAS/mTORC2 interaction. Furthermore, we are evaluating whether SIN1 has also functions independent of the mTORC2 complex in melanoma, by searching for other partners of SIN1 by PLA in melanoma lines.
Results
Our preliminary results show that mTORC2 interacts with NRAS in BRAFm melanoma and that inhibiting the NRAS/mTORC2 interaction reduces the proliferation of melanoma cell lines and in particular those resistant to TT. This leads us to develop inhibitors to specifically target resistant melanomas.
Conclusions
The results of this project will provide us a better understanding of the mTORC2 signalling pathway in the development of BRAFm melanoma and its response to TT. Given the lack of a specific mTORC2 inhibitor at this time, SIN1 could be an ideal therapeutic target to aim for mTORC2.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fondation ARC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - Bcl-xL prevents the arginine starvation induced by PEGylated arginine deiminase (ADI-PEG20) from inducing apoptosis
Presenter: Brian Van Tine
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Cationic dendrimers as prospective vehicles of therapeutic nucleic acids into tumor cells: Approaches, advantages and challenges
Presenter: Nadezhda Knauer
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Quantitative indicators of TREC and KREC excision rings in malignant neoplasms
Presenter: Alexander Sultanbaev
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Presenter: Gulsah Nomak
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Prediction of radiation responses in patients with locally advanced rectal cancer with a patient-derived organoid-based radiosensitivity model
Presenter: Samart Phuwapraisirisan
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Co-expression analysis of genes encoding proteasome subunits and XPO1-related proteins in the Cancer Genome Atlas (TCGA) and the Gene Tissue Expression (GTEx) databases as a tool to devise new treatment strategies
Presenter: Vito Spataro
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - Microsomal triglyceride transfer protein as a prognostic and therapeutic marker for brain cancer
Presenter: Ryuk Jun Kwon
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Choline transporter-like protein 1 is a novel molecular target for the treatment of hepatocellular carcinoma
Presenter: Masato Inazu
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Knockout of lncRNA-CCAT1 with the use of CRISPR-Cas9 system and G7 PAMAM dendrimers influences apoptosis and proliferations of NSCLC cells
Presenter: Mateusz Iwanski
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Censoring imbalance in ACIS trial for prostate cancer
Presenter: Noa Zimhony-Nissim
Session: Cocktail & Poster Display session
Resources:
Abstract